Iodide

Iodide

SCHEMBL990197

C(=C\COC1CCCCO1)\CC[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[I-]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HIF1A Q16665 1/20 0.33
CHRNA7 P36544 8/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
SLC6A3 Q01959 2/20 0.30
OPRM1 P35372 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL31076166 0.84 MEN1 (0.42) KDM4CMEN1KMT2AHIF1ACHRNA7
Iodide SCHEMBL28851041 0.82 MEN1 (0.46) KDM4CMEN1KMT2ACHRNA7L3MBTL1
Iodide SCHEMBL7755123 0.80 MEN1 (0.49) KDM4CMEN1KMT2AHIF1ACHRNA7
Bromide SCHEMBL7324390 0.79 KDM4C (0.47) KDM4CMEN1KMT2AHIF1ACHRNA7
Bromide SCHEMBL11517500 0.77 MEN1 (0.49) KDM4CMEN1KMT2AHIF1ACHRNA7
Bromide SCHEMBL5214341 0.77 MEN1 (0.49) KDM4CMEN1KMT2AHIF1ACHRNA7
Bromide SCHEMBL29196153 0.76 MEN1 (0.44) KDM4CMEN1KMT2AL3MBTL1NPC1
Hydrochloric Acid SCHEMBL6205586 0.76 KDM4C (0.43) KDM4CMEN1KMT2AHIF1AL3MBTL1
Bromide SCHEMBL8442020 0.76 MEN1 (0.51) KDM4CMEN1KMT2AHIF1ACHRNA7
Bromide SCHEMBL11354372 0.76 MEN1 (0.51) KDM4CMEN1KMT2AHIF1ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822542-B2 Isoketal scavengers and mitigation of disorders involving oxidative injury VANDERBILT UNIVERSITY (US) 2014-09-02 US disclosed
EP-2477594-A1 ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY Vanderbilt University (US) 2012-07-25 EP disclosed
US-20120157501-A1 ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY VANDERBILT UNIVERSITY 2012-06-21 US disclosed
WO-2011008202-A1 ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY VANDERBILT UNIVERSITY (US) 2011-01-20 WO disclosed
US-7705054-B1 Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases VANDERBILT UNIVERSITY (US) 2010-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157501-A1 ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY PDXK, KYNU, FN3K KDM4C 1420/4885MEN1 4712/4885KMT2A 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.